{'fraction_non_alphanumeric': 0.03815580286168521, 'fraction_numerical': 0.014308426073131956, 'mean_word_length': 5.237623762376238, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 2, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
PCP Occurring in HIV Patients Under HAART: Assessment of Specific Immunity Against P. carinii

The beneficial effect of highly active anti-retroviral therapy (HAART) in reducing opportunistic infections associated with AIDS is currently attributed to viral suppression and T-cell reconstitution. Observational studies suggested that P. carinii prophylaxis can be safely discontinued when CD4>200 [2]. We recently observed hvo P. carinii pneumonia (PCP) with CD4 >250 under stable HAART. We decided to study lymph-proliferative in vitro response to non-specific and P. carinii-specific antigens (PcAg) in index cases and controls.